Edward Bromfield, MD
Division Chief, Brigham and Women’s Hospital,
Dr. Edward B. Bromfield, is Chief of the Division of Epilepsy and Sleep in the Department of Neurology at Brigham and Women’s Hospital, and Associate Professor of Neurology at Harvard Medical School. His clinical and research interests related to epilepsy include medical and surgical treatment, neuroimaging, quality of life, genetics, brain tumors, pregnancy, status epilepticus, and intracranial EEG. He has been active in the Epilepsy Foundation of Massachusetts and Rhode Island where he previously served as Chair of the Professional Advisory Board and as President of the Board of Directors.

Dr. Bromfield earned a AB, magna cum laude, in Psychology at Harvard College in 1973 and a MD at Harvard Medical School in 1983. He is currently on the Professional Advisory Board of the national Epilepsy Foundation.

Peter LeWitt, MD
Professor, Wayne State University School of Medicine
Dr. Peter LeWitt was appointed Professor of Neurology at Wayne State University School of Medicine in 1989. A Board-certified neurologist sub-specializing in movement disorders, his clinical practice is located at the Clinical Neuroscience Center in Southfield, Michigan. Dr. LeWitt is interim chairman of neurology and director of the neuroscience laboratory research program at William Beaumont Hospital (Royal Oak, Michigan) investigating the mechanisms of neurological disease and early diagnostic markers.

Dr. LeWitt is the author of more than 300 publications on clinical and basic neuroscience and in 1999 edited PARKINSON’S DISEASE: THE TREATMENT OPTIONS. He has served as an educator for the American Academy of Neurology and numerous teaching programs in United States and elsewhere. He has been a scientific review consultant for the National Institutes of Health, Veterans Administration, United Parkinson Foundation, the International Essential Tremor Foundation and the Tourette Syndrome Association. Dr. LeWitt is president of the Michigan Parkinson Foundation and has directed the National Parkinson Foundation’s Center of Excellence in Michigan. He has been elected secretary of the Movement Disorder Society, an international professional organization of Parkinson’s disease and movement disorder specialists and researchers. Since 1986, Dr. LeWitt has been a steering committee member and investigator for clinical trials conducted by the Parkinson Study Group and by a National Institutes of Health research consortium on neuroprotection in Parkinson’s disease.

His undergraduate, research, and medical education is from Brown University, with additional post-graduate medical and research training at the University of Pennsylvania School of Medicine, Stanford University School of Medicine, and the National Institutes of Health.

Michael Murphy, MD, PhD
CMO, Senior Vice President,Torreypines Therapeutics
Dr. Michael Murphy is the Chief Medical Officer and Senior Vice President of Drug Discovery and Development for Torreypines Therapeutics. Responsibilities include the supervision of discovery activities predicated upon a genetic etiology for neurological disorders particularly late onset Alzheimer’s disease, and discovery/preclinical and clinical development activities for disease modification strategies in neurodegeneration. Current preclinical development programs include direct supervision of staff responsible for activities in medicinal chemistry, target identification, and lead optimization leading toward regulatory enabling preclinical studies and first-in-man investigations. Direct professional contributions lie in the creation of translational research opportunities in early-stage clinical development for small molecules in central nervous system disorders. Prior to joining Torreypines Therapeutics, Dr. Murphy served both as President of the Clinical Research Organization then Chief Medical and Scientific Officer for Ingenix, a division of UnitedHealth Group.

Dr. Murphy’s professional interests emphasize integration across disciplines in the discovery, development, and commercialization of experimental therapeutics with particular focus upon clinical trial methodology across diverse therapeutic areas and phases of development. He is boarded in psychiatry and has a doctorate in pharmacology, with training at Tulane University, Stanford University, and the Mt. Sinai School of Medicine. He in a faculty member within the Center for Experimental Pharmacology and Therapeutics, Harvard-MIT Division of Health Sciences and Technology, and a lecturer for Research Fellows within a two-year Clinical Investigator Training Program.

John Nutt, MD
Professor, OHSU Parkinson Center of Oregon
Dr. John Nutt is currently a Professor in Neurology, and Physiology & Pharmacology, the Director at the OHSU Parkinson Center of Oregon (PCO) and the Director at the Portland VAMC Parkinson’s Disease Research, Education and Clinical Center (PADRECC). Dr. Nutt is dedicated to improving the lives of those with Parkinson’s disease through groundbreaking research and clinical care. He sees patients at the OHSU Movement Disorders Clinics, the OHSU Botox Clinic and the VA Movement Disorder Clinic. Dr. Nutt is dedicated to improving therapies for movement disorders, particularly Parkinson’s disease. Many of his studies focus on the dopaminergic system and symptomatic therapy. However, increasingly, trials exploring neuroprotection and neurorestorative therapies are underway. In addition to interventional trials, he has interests in gait and balance and in the genetics of Parkinson’s disease. The pharmaceutical industry often seeks his advice on concepts and studies regarding new therapies for Parkinson’s disease.

Dr. Nutt instructs medical students and neurology residents at the Movement Disorders Clinics. Outside of the Movement Disorders Clinic, Dr. Nutt is an attending physician at both OHSU and the Portland VA in which he instructs neurology residents and medical students. He has also mentored 6 Fellows at the Parkinson Center of Oregon over the last 20 years.

Dr. Nutt earned a BA in biochemistry at Rice University in 1965 and a MS in Pharmacology and a MD at Baylor College of Medicine in 1970. Neurology training was completed at University of Washington. Clinical fellowships included two years at the Addiction Research Institute in Lexington, KY (1971-73) and two years at NIH-NINDS Experimental Therapeutics Branch (1976-78). In 1978, Dr. Nutt joined OHSU as an Assistant Professor of Neurology and Pharmacology.